This Article Full Text Full Text (PDF) All Versions of this Article: 23/1/90    most recent 01.ATV.0000046229.77566.E5v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, J. Articles by Briggs, M. R. Search for Related Content PubMed PubMed Citation Articles by Liu, J. Articles by Briggs, M. R. Related Collections Coumarins CPR and emergency cardiac care CV surgery: other Endothelium/vascular type/nitric oxide

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:90.)
© 2003 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Synergistic Activation of Human LDL Receptor Expression by SCAP Ligand and Cytokine Oncostatin M

Jingwen Liu; Fang Zhang; Cong Li; Meihong Lin; Michael R. Briggs

From the VA Palo Alto Health Care System (J.L., F.Z., C.L., M.L.), Palo Alto, Calif, and Pharmacia Corp (M.R.B.), St Louis, Mo.

Correspondence to Jingwen Liu, PhD (154P), VA Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA 94304. E-mail Jingwen.Liu{at}med.va.gov

Objective— A recent study identified a new class of compounds designated as the sterol-regulatory element binding protein (SREBP) cleavage-activating protein (SCAP) ligands that putatively bind to SCAP, leading to increased LDL receptor (LDLR) expression. In this study, we examined the effects of SCAP ligand GW707 in comparison with lovastatin and cytokine oncostatin M (OM) on the regulation of LDLR expression in cultured HepG2 cells.

Methods and Results— Our studies uncovered several new features that distinguish SCAP ligand from lovastatin, a classic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and from OM, which utilize an SREBP-independent regulatory pathway. We show that the induction of LDLR mRNA expression by GW707 is not affected by intracellular cholesterol but is completely abolished by blocking de novo protein synthesis. Moreover, the effects of GW707 but not lovastatin on LDLR promoter activity, mRNA expression, and uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanin perchlorate–LDL are markedly enhanced by OM. We further demonstrate that the amounts of the mature form of SREBP-2 translocated to the nucleus under GW707 treatment are increased by costimulating cells with OM.

Conclusions— Our studies provide the first evidence that higher levels of LDLR expression and function can be achieved through simultaneous stimulation of the SREBP-dependent and SREBP-independent pathways, suggesting a strategy to develop an adjunct therapeutic intervention utilizing both pathways.

Key Words: LDL receptor • SCAP ligand • oncostatin M • sterol-regulatory element • sterol-independent regulatory element

This article has been cited by other articles:

				M.-H. Hsu, U. Savas, K. J. Griffin, and E. F. Johnson Regulation of Human Cytochrome P450 4F2 Expression by Sterol Regulatory Element-binding Protein and Lovastatin J. Biol. Chem., February 23, 2007; 282(8): 5225 - 5236. [Abstract] [Full Text] [PDF]

				P. Abidi, W. Chen, F. B. Kraemer, H. Li, and J. Liu The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms J. Lipid Res., October 1, 2006; 47(10): 2134 - 2147. [Abstract] [Full Text] [PDF]

				W. Kong, P. Abidi, F. B. Kraemer, J.-D. Jiang, and J. Liu In vivo activities of cytokine oncostatin M in the regulation of plasma lipid levels J. Lipid Res., June 1, 2005; 46(6): 1163 - 1171. [Abstract] [Full Text] [PDF]